A5100434151- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- HER2/EGFR in Cancer Research
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
- Head and Neck Cancer Studies
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Growth Hormone and Insulin-like Growth Factors
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Bone health and treatments
- Biochemical and Molecular Research
- Natural Antidiabetic Agents Studies
- Wound Healing and Treatments
- Bacterial Identification and Susceptibility Testing
- Chronic Kidney Disease and Diabetes
- Blood disorders and treatments
- Cell death mechanisms and regulation
- Immune cells in cancer
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Colorectal and Anal Carcinomas
- DNA Repair Mechanisms
Nanjing Medical University
2021-2025
Jiangsu Province Hospital
2020-2025
First Bethune Hospital of Jilin University
2022-2025
Jilin University
2021-2024
Bristol-Myers Squibb (United States)
2022
University College London
2019-2021
The First People’s Hospital of Lianyungang
2021
First Hospital of Jilin University
2021
University College London Hospitals NHS Foundation Trust
2021
Kangda College of Nanjing Medical University
2021
CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab cisplatin/carboplatin fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma head and neck (R/M SCCHN) post-platinum therapy. Nivolumab IC as first-line treatment also OS R/M SCCHN who progressed on platinum therapy for locally advanced disease in adjuvant setting 1-year follow-up. present long-term follow-up receiving...
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with favorable safety profile demonstrated in preclinical phase I studies. BRIGHT‐1 aimed to further explore the efficacy of bireociclib monotherapy patients locally advanced, recurrent or metastatic, hormone receptor‐positive human epidermal growth factor receptor 2‐negative (HR + /HER2 − ) breast cancer who had progressed on after prior chemotherapy endocrine therapy advanced...
In this study, we identified microRNAs that regulate the expression of programmed death-ligand 1(PD-L1) in osteosarcoma and investigated their role PD-L1-targeted immunotherapy. MicroRNA sequencing analysis showed PD-L1 is regulated by microRNA-200a U2OS, 143B, K7 cells. MicroRNA-200a overexpression induced upregulation CD8+ T cells co-cultured with microRNA-200a-overexpressing reduced survival, proliferation, secretion granzyme B perforin. The same phenomenon was also observed K7-derived...
Abstract Background This first-in-human phase 1 trial is to evaluate the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab, a full-length, fully human anti-PD-L1 monoclonal antibody, in Chinese patients with advanced malignancies. Methods Eligible unresectable or metastatic solid tumors lymphomas were enrolled 1a receive sugemalimab following modified 3 + design. The primary endpoints included tolerability, recommended Phase 2 dose (RP2D). In 1b, 7 selected types...
The anticancer effects of immune checkpoint inhibitors (ICIs) have been widely examined recently. Although ICIs progressively improved for successful gastric cancer treatment, different trials such as pembrolizumab and nivolumab yielded variable response rates. Strategies to further improve the efficacy are still needed. Previous studies shown that de novo DNA methylation is acquired by PD1+CD8+ tumor-infiltrating T cells (TILs), which cause a hierarchical downregulation cytokines...
To evaluate the diagnostic value of combining neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte (PLR) or lymphocyte-monocyte (LMR) with carcinoembryonic antigen (CEA) in patients colorectal cancer (CRC).The performance inflammatory makers and CEA was evaluated cohort 1 (664 CRC, 336 polyps 664 healthy controls) validated 2 (87 CRC 87 by using receiver operating characteristic curve analysis.In 1, NLR, PLR levels were significantly higher, while LMR markedly lower than controls. The...
Importance The bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective may help increase access patients with solid tumor–related bone metastases. Objectives To establish the biosimilarity MW032 metastases based on large-scale study. Design, Setting, Participants In this randomized, double-blind, phase 3 equivalence trial, tumors metastasis were recruited from 46 clinical sites China. Overall, 856...
We aimed to retrospectively analyze the predictors of immune checkpoint inhibitors (ICIs)-efficacy in patients with advanced pancancer who were treated various ICIs real world and focused on correlation between ICIs-efficacy immune-related adverse events (irAEs). analyzed data from 103 receiving First Hospital Jilin University January 1, 2016 August 2020. Survival probabilities progression-free survival (PFS) overall (OS) estimated using Kaplan-Meier curves log-rank tests multivariate Cox...
To investigate whether red blood cell distribution width (RDW) is a marker of the risk Henoch–Schonlein purpura (HSP) nephritis (HSPN), total 669 HSP patients and 168 healthy controls were included in this retrospective study. Two hundred fifty-six (38.3%) had kidney involvement. Compared with group, RDW was significantly higher HSPN group (P < .001). Binary logistic regression identified that independently associated age, RDW, platelet, cholesterol (odds ratio = 1.409, 1.353, 0.996, 2.019,...
To investigate the clinical significance of naïve T cells, memory CD45RA+CD45RO+ and naïve/memory ratio in non-small cell lung cancer (NSCLC) patients.Pretreatment peripheral blood samples from 76 NSCLC patients 28 age- sex-matched healthy volunteers were collected tested for immune cells by flow cytometry. We compared expression these between controls evaluated their predictive roles survival cox proportional hazards model.Decreased CD4+ CD8+ ratios CD4+CD45RA+CD45RO+ increased observed to...
Breast cancer is the most common worldwide. JWA a microtubule-associated protein that has been identified as tumor suppressor, and its downregulation in tumors an independent adverse prognostic factor. The objective of this study was to explore expression, regulation, mechanism trastuzumab-resistant breast cancers. In study, we found expression lower cancers than trastuzumab-sensitive Furthermore, it confirmed overexpression inhibited proliferation promoted apoptosis both vitro vivo....
About 20% of breast cancer patients are positive for HER2.The efficacy current treatments is limited by primary and secondary resistance to trastuzumab.tRNA-derived fragments (tRFs) have shown crucial regulatory roles in various cancers.This study aimed evaluate the role tRF-27 regulating HER2-positive against trastuzumab.tRF-27 was highly expressed trastuzumab-resistant cells, its expression level could predict trastuzumab.High promoted growth proliferation trastuzumab-exposed...
Abstract Background Re‐designing services and processes to meet growing demands in chemotherapy is necessary with increasing treatments. There little evidence guiding the timing thresholds be attained of pre‐chemotherapy blood assessments, namely neutrophils. Methods A survey was developed distributed health professionals United Kingdom (UK) examine current practice threshold values neutrophils platelets before treatment administration. This followed by a retrospective cohort study, using...
Pseudoprogression is a unique, uncommon phenomenon that often hints at good prognosis. To date, there has been no report of complete remission after pseudoprogression. Here, we successful treatment metastatic renal clear cell cancer, using anti-PD-1 antibodies combined with autologous RetroNectin-activated cytokine-induced killer cells, in two patients who were failed to multitargeted kinase inhibitors. After early pseudoprogression, was achieved. At present, one patient stopped therapy for...
Abstract Lapatinib is widely used in the later lines treatment of HER2 positive metastatic breast cancer (MBC). EGF104900 study suggested that among patients who experienced progression on prior trastuzumab‐containing regimens, lapatinib plus trastuzumab had better effects than alone. However, no evidence was discovered terms capetabine compared with chemotherapy, as well a after lapatinib. We evaluated medical records retrospectively all MBC disease progressed regimens (advanced setting)...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Li W, Wang Y, Kellner D, Xu L, Mai L. Clinical immunologyEfficacy of cytokine-induced killer cells in the treatment elderly patients with metastatic pancreatic adenocarcinoma. Central European Journal Immunology. 2015;40(2):188-193. doi:10.5114/ceji.2015.52833. APA Li, W., Wang, Y., Kellner, D., Xu, L., & Mai, (2015). Immunology, 40(2), 188-193. https://doi.org/10.5114/ceji.2015.52833 Chicago Wei, Yaomei Daniel...
Abstract Trastuzumab resistance remains a challenge for HER2 positive breast cancer treatment. Targeting metabolic reprogramming would provide novel insights therapeutic strategies. Here, we integrated metabolomics, transcriptomics and epigenomics data of trastuzumab sensitive primary resistant to identify alterations. Aberrant cysteine metabolism was discovered in at both circulating intracellular levels. The inhibition SLC7A11 starvation could synergize with induce ferroptosis....